

REVIEW ARTICLE

Conventional and Nano- Antibodies and Their Future Uses

Awatif Hameed Issa, Department of Pathological Analyses, College of Science, Basrah University. Mobile: +9647801059989

Email: awatifhssa@uobasrah.edu.iq

ORCID: <http://orcid.org/0000-0001-8953-5308>

AbdAlAllah Abd Alhesin, College of Pharmacy, Basrah University.

Email: abdulelah.suhain@uobasrah.edu.iq

ORCID: <http://orcid.org/0000-0001-9781-4999>

Rana Shather Aljabery, Paediatric Hospital, Basrah Health Authority, Ministry of Health. Email: ranaaljabery@gmail.com

ORCID: <https://orcid.org/0000-0001-6757-7603>

Correspondence author: Awatif Hameed Issa, Department of Pathological Analyses, College of Science, Basrah University. Mobile: +9647801059989

Email: awatifhssa@uobasrah.edu.iq

Received: 2/6/2019

Accepted: 24/7/2019

Published: 1st August 2019

Abstract

Antibodies are the end products of the humoral immune responses and are produced exclusively from plasma cells. The natural structure is glycoprotein also called immune protein because their function is defence by specialization. The main functions of antibodies are opsonisation, neutralization, agglutination, precipitation and complement activation “fixation”. Conventional antibodies consists of two heavy chains and two light chains and can divided into five Classes, based on diversity in the amino acid sequences in the constant region of heavy chains. Also antibodies can be classified into three different classes including polyclonal, monoclonal and recombinant antibodies dependent on immunotechnology applications. In addition to conventional antibodies in 1993 Hamers-Casterman et al, discover antibodies contain only two heavy chains, and produce from few animal species. These review abductors on these types of antibodies and the extent of independent thinking to be used in the treatment of incurable disease such as cancers.

Keywords: Antibodies; Immune protein; Light chain, Heavy chain; Conventional antibodies; Nano-antibodies.

Conventional Antibody

Conventional antibodies (whole size) are a glycoproteins, secreted by differentiated B-cells to named plasma cells and response to foreign antigen “immunogenic” [1], these antibodies are named immunoglobulin [2], which act as a critical part of the humoral immune response by recognizing and reacting specifically with foreign bodies [3], the primary function of antibodies is to bind specifically to an antigen and elicit an immune response, and destruction of extracellular pathogens, and prevention against the spread of intracellular infections, and protecting the host from infection.

Conventional Antibody Structure

Conventional immunoglobulin G (IgG) consists of two heavy chains and two light chains. The heavy chains consist of a constant region (C_H), organized into three constant domains (C_{H1} - C_{H3}) and one variable domain (V_H). The C_{H1} and C_{H2} domains are linked by a hinge region. The light chains are composed of one constant (C_L) and one variable domain (V_L). The paired V_H and V_L domains are responsible for antigen binding; each antibody (monomer or basic unit) has a Y-shaped unit [4]. The basic unit of a complete antibody consists of a four polypeptide unit containing two identical large heavy chains (50–70 kDa), and two same size of small light chains “25 kDa” [5] bound together by disulfide bonds [6], and the hinge region at the point of the Y structure has flexibility, each polypeptide chain consist of :

- Constant region “crystallizable region (Fc)”
- Variable region “antigen-binding region (Fab)”

Constant region is the same for all antibodies, and it's not recognized as antigen, but it's responsible for mediating effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis, antigen presentation to the immune system, degranulation, complement-mediated lyses, and effectors function which triggers the elimination of antigen like complement activation and macrophage activation, while the variable region is responsible for recognized the antigens and its includes one variable region (variable light or V_L) of the light chain and one constant region (C_L) of the heavy chain [7, 8], and forms the antigen-binding region (Fab) of the antibody, where the complementarily-determining regions (CDRs) can be located [9]. The CDRs from the antigen-binding sites of antibody and recognized the antigen with specificity, the Fab part retains the antigen binding activity while the Fc part form most of the constant region of the heavy chains [10].

Antibodies Classes

The antibodies are divided into five isotype, based on diversity in the amino acid sequences in the constant region of heavy chains [11] are IgG (Gamma heavy chains), IgM (Mu heavy chains), IgA (Alpha heavy chains), IgD (Delta heavy chains) and IgE (Epsilon heavy chains). The main functions of antibodies are opsonisation, neutralization, agglutination, precipitation and complement activation “fixation” [12]. As described above classes of antibodies, the IgM is the first antibodies to be produced in primary response; it's expressed on the B cell and in a secreted form (pentamer) with very high avidity, and it's responsible for activation of phagocytosis [13]. An IgA class antibody is mainly found in mucosal surfaces such as the gut, respiratory tract and prevents colonization by pathogens [14]. IgE is an important of antibodies contributed in defense against parasites and play a critical role in allergic diseases [15], while IgD isotype is found just in a little amounts as antibody but its function still unresolved [16] and finally IgG are with 70-75% of the total immunoglobulin the most abundant antibodies [15], the only antibody capable of crossing the placenta to give passive immunity to the fetus.

Antibodies Categories

Antibodies can be classified into three different classes including ploy clonal, monoclonal and recombinant antibodies [17].

- Polyclonal antibodies (PAb) are heterogeneous antibody mixtures that are derived from several plasma cell lines. Because polyclonal antibodies

comprise a complex of different antibodies that have numerous paratopes, they also have excellent properties for recognizing antigens [18, 19].

- Monoclonal antibodies (MAb) are a homogeneous antibody coming from a single B lymphocyte clone and produced in monoclonal antibodies format have a unique high specificity against a single epitope [19].
- Recombinant antibodies (RABs) are antibodies generated using molecular biological methods. They are aimed to improve the stability, sensitivity, selectivity and immobilization properties in diagnostic applications [20].

Conventional Antibody Applications

Because of the high specificity of antibodies against several antigens, the antibodies are used as a study instrument for target detection, helping in medical diagnosis and therapy, therefore the antibody is considered basically for a very broad range of application and then orientation to produce the monoclonal antibody (mAbs) and antibody fragments (parts) which have become a significant segment of industrial and academic research due to their proven efficacy, safety, and manufacturability profiles [21].

Monoclonal antibody production is an old immunological technique with great applications in the fields of biochemistry, immunology, biotechnology and applied biology among others [22], it is used in immunodiagnostic techniques as reagents to detect antigen of the causative agents or antibodies detection against the causative agents [23] like ELISA, western blot, immunodot blot, flow cytometer, immunohistochemistry, radioimmunoassay (RIA), microscopy (electron, fluorescence, confocal) and other biotechnology applications [22,24,25].

The monoclonal antibodies have been used in cancer treatments [26], and it relies on small-molecule drugs that easily enter tumor cells or monoclonal that connect to specific target on their surface and is used as immunotherapies target different goals like the blockade of oncogenic pathways with subsequent effect on cell growth and apoptosis [27], the blockade of the formation of new blood vessels [28], the modulation of immune response against tumor cells [29], opposite polyclonal antibodies, the monospecificity of monoclonal antibodies improve targeting of a single epitope.

Despite the success of antibodies as treatment in patients but they have the disadvantages that their inability to penetrate into certain tissues due to their big size and heavy ~150 kDa [30], also the Fc domain will stimulate the body's immune response and its target bound molecules for destruction, which may be detrimental to the patient's health; resistance to accessibility to target antigen and high cost have restricted their widespread application in patients, low stability; therefore, multiple studies are ongoing to develop new ways for improving the specificity of monoclonal antibodies, and the cost-effective expression systems to overcome the limitations mentioned previously [31].

Nanobodies (Nbs)

In addition to conventional antibodies H_2L_2 -type IgGs [32], in the serum of Camelidae family like (Bactrian camels, dromedaries and llamas), also possess special IgG antibodies homodimeric H_2 -type antibodies which were called heavy chain-only antibodies (HCAbs) IgG [33], which as a part of the humoral immune response known as heavy-chain antibodies "HCAbs" [32,34]. These antibodies contain only two heavy chains, while the light chain and C_{H1} domain are absent, and lacking C_{H1} is necessary for anchoring the light chain in conventional antibodies [35, 36].

The C-terminal VH region derived from HCAs its named variable domain (V_{HH}), also referred to single domain antibody (sdAbs) or " Nanobody®" a trade name of Ablynx" [37-39] which without VL. The hinge region joined directly to this domain, and the extended hinge region in heavy chain antibody (HCAs) due to its high proline content, and promotes their flexible and stability the antibody [40,41]. In cartilaginous fishes like sharks, rays, and skates [42,43] are have heavy-chain antibodies (HCAs) which formed two single-domains antibodies (V_{HH} or nanobody) are called 'immunoglobulin variable new antigen receptor (Ig_{VNAR} fragments).

In general the nanobodies have a molecular weight about 12–15 kDa much smaller than conventional antibodies with molecular weight about (150–160 kDa) and even smaller than antigen binding site “~50 kDa” and single-chain variable fragments “~25 kDa” of conventional antibodies [44,45].

Expression of Antibodies in Endoplasmic Reticulum (ER).

The Camelidae family has three major subclasses of circulating γ immunoglobulins (IgG): IgG₁, IgG₂, and IgG₃. Immunoglobulin G₁ is a heterotetrameric antibody (i.e. two heavy chains and two light chains) while IgG₂ and IgG₃ are homodimers of only heavy chains (i.e. two heavy chains, while light chains and C_{H1} are absence). Immediately after translation, heavy and light chains combine together in the endoplasmic reticulum. The major ER protein is called heavy chain binding protein (BiP) [46]. A nascent heavy chain is bound by BiP immediately after translation and is retained until a light chain can replace BiP [5]. If a light chain is absent, the heavy chain/BiP complex is bound by E3 ubiquitin ligase complex and transported across the membrane to the proteasome [47]. BiP binds specifically to the C_{H1} segment of the heavy chain [48], and retains the heavy chain in the endoplasmic reticulum until BiP is exchanged for a light chain. Since C_{H1} regions are not present in antibodies belonging to the camel class IgG₂ and IgG₃, such antibodies cannot be retained by BiP and are exported.

The mechanism of removal of exon encoding C_{H1} during mRNA processing [35], camelids carry a nucleotide G to a point mutation that disrupts the consensus-splicing site at the 5' end of the intron between the C_{H1}-hinge exons and provokes the elimination of the C_{H1} region from the messenger ribonucleic acid by splicing [49,50].

Characteristics and Advantages of Nanobodies

Nanobody (Nb) is a peptide chain comprising of (110) amino acid and forming one variable domain of heavy chain antibody IgG [51], the conventional IgG were present which contributed up to 75% of all serum in Camelidae family [34], the immunoglobulin IgG is divided into subclasses are IgG₁, IgG₂, IgG₃.

The immunoglobulin IgG₁ is a conventional antibody with a molecular weight about ~150 kDa, while two other immunoglobulin fractions are non-conventional antibodies are IgG₂ and IgG₃; with molecular weight ~90 kDa. These nanobodies have similar affinity and specificity of conventional antibodies [52] to different antigens, but it has unique features [53] that are not accessible to conventional antibodies:

- Nanobodies have small size only tenth the size of conventional antibodies that lead to more effective permeability in tissues [45, 52], especially translocation through the blood-brain barrier [54], than of conventional antibodies. Because of their size in the nm range, hence the term 'nanobody' [45]. The diameter and length of VHH crystals are only about 2 and 4.5 nm, respectively, making them the smallest functional antibody fragments known [55].

- Nanobodies more heat-resistant survive at a temperature 90 °C for an hour without loss of their ability to bind antigens [56, 57].
- Nanobodies are less lipophilic and more soluble due to the increase of net charge of the protein [58] compared to the conventional antibody (V_H) and may be due to the hydrophilic amino acid substitution found in the region of framework 2.
- For conventional antibodies, it is established that upon antigen binding, the ADCC and complement-dependent cytotoxicity are triggered by the Fc region [59, 60]. These two mechanisms play a critical role in the process of tumor elimination, as they both stimulated activation of cell lyses, and hence apoptosis cascades [59], for this reason, it was proposed to extent nanobodies without an Fc region [60].
- Nanobodies easy eliminated reanly unlike whole antibodies [33, 44, 45].
- Nanobodies can interact with a greater number and different of epitopes than of conventional antibodies [52, 61], and opened a new window in breast cancer therapy [62].
- Nanobodies are easy to produce in bacteria [63], yeast like *Pichia pastoris* and *Saccharomyces cerevisiae* [64] or in plants [65], and enabling large-scale production at reasonable costs [66].
- Nanobodies are considered to be non-immunogenic due to their high similarity with human V_H sequences; these unique properties triggered numerous applications in fundamental research, diagnostics, and therapy [34, 45, 66, and 67].
- Nanobodies are capable of recognizing haptens and cryptic epitopes that are not accessible to conventional antibodies [68].
- Nanobodies can bind to their targets with a high affinity and can be produced by simple methods with high yields [69].
- Nanobodies also demonstrate high stability even on exposure to extreme conditions such as very low/high pH and temperature [70].
- Nanobodies are procured by cloning the VHH gene and panning by phage display [49, 71] by using M13 helper phage.
- Nanobodies consist of four framework regions (FR1, FR2, FR3, and FR4) which form the core structure of the immunoglobulin's domain, and three complementarily-determining regions CDRs [34], the longest being CDR3 [72] that are involved in antigen binding which plays a critical role in their stability and binding affinity [34,45,73,74], this due to possess an additional disulfide bridge linking the CDRs (CDR1 and CDR3) also CDR3 is longer than CDR3 in conventional antibodies and that lead to form finger-like structure that enter into cavities on the surface antigen [34,73,75].

Nanobodies Applications

Because of these unique properties of nanobodies triggered numerous applications in fundamental research, diagnostics and therapy [34, 45, 66, 67]. So far, fast and reliable in vivo diagnosis of cancer at an early stage of disease progression remains a major challenge. Furthermore, in cancer diagnostic tests, nanobodies besides diagnostic applications for in vivo imaging due to their fast blood clearance and good tissue penetration, nanobodies have proven useful as specific drug delivery vehicles in tumor targeting [76]. The small size of this particle can ensure delivery of hidden antigens to the cancerous tissue without effecting healthy cells while healthy cells stay unharmed. It was reported that a nanobody specifically recognizes lysozyme targeted tumors transgenic for lysozyme [77]. Further potential therapeutic areas

include inflammation [38, 76]. Nanobodies can be used also to mark cells for sorting by flow Cytometry or magnetic beads.

Nanobodies Diversity

The development of conventional antibody interacts of V_H specifically with the V_L domain together. In the absence of a V_L domain, these lead to cause unspecific aggregation of HCABs. Generally, the heavy chain variable domain (both V_H and v_{HH}) is encoded by multiple gene segments [10], the V (variable) gene segment, the J (joining) gene segment and the D (diversity) gene segment [78]. During B cell differentiation, the gene segments of antibody is specifically legated in a process named VDJ recombination to form a whole heavy chain variable exon [79] in which the V gene segment encodes the CDR1 and CDR2, while the CDR3 is formed by the joining of the three gene segments. In order not for the amino acid substitutions which are specific for nanobodies (V_{HHs}), camelids heavy chains to arise from the same V genes as conventional antibodies [35]. Nanobodies (V_{HHs}) are encoded by different set of V segments (~40 V segments).

Display Technologies to Obtain Recombinant Monoclonal Antibodies

In addition to the aid DNA engineering, surface display has been commonly used to engineered and isolate peptides, antibody fragments of scFv, and a single domain for selection monoclonal antibodies and using for the clinical application. The main advantage of the in vitro display technology is the possibility to obtain antibodies to any kind of targets and epitopes because the construction of a naïve or synthetic antibody repertoire is not dependent on an in vivo immune response [80], these display technologies such as display of (DNA, bacterial, yeast, ribosome, mRNA and phage).

DNA display

DNA display technology is a simple technique compared with other fully in vitro display technologies, with fewer steps [81]. This display technique is used for in vitro selection of peptide ligands from a large library of peptides displayed on their encoding DNAs [81,82]. The advantages of this technology not require the RNase-free conditions are not need for the selection step because of not need the reverse transcription step. While the disadvantage of DNA display technology devoid of a robust platform and knowledge in comparison to other in vitro display technologies.

Bacterial and yeast display

Cell surface display systems have been developed for different host microorganisms, including bacteria and yeast cells [83, 84]. Bacterial and yeast display is the other in vitro display technology, both of these techniques depended on fusing the gene of the binder library to respective surface proteins, the bacteria and yeast can be screened via flow Cytometry. The generation of nanobodies by bacterial fermentation is simpler, quicker and cheaper than conventional antibodies generation [85].

Bacterial display technology is uses bacteria cells like *Escherichia coli*, as a host for expression and engineering of antibodies fragments like single domain antibody [86, 87]. On the other hand, yeast display technology uses yeast cells to display exogenous peptides or antibody fragments on the cell surface of the host cell [88].

Ribosome and mRNA display

Messenger RNA and ribosome display technologies as appearing a revolutionary in vitro display platform to avoid cell transformation steps. Ribosome display including the in vitro transcription and translation of a DNA library; and independent of *E. coli* transformation. The characteristics of mRNA display and

ribosome display technology helps to build much larger libraries [89] than the other in vitro display technologies because it avoids the library size limitation of phage and yeast display technologies which rely on the efficiency. The other advantage of this technology is the extensive use of PCR that contributes to the provider of more diversity to the library by mutations. In addition, mRNA and ribosome display platform can be used for the selection of novel molecules, including antibody fragments, and for affinity maturation of antibodies [90].

Phage display

Phage display is a powerful and robust technology, it was the first technology introduced by George Smith in 1985, that allows display of Nbs and other Ab fragments with high affinity and specificity to several target antigen on the surface of filamentous bacteriophages such as M13 or f1 [91-93], which infects *E. coli* through the F pilus. Phage display facilitates selection of proteins, peptides, or antibodies with suitable binding properties from a large collection of variants, so named phage display library. Individual phages comprise a defined binder on the surface and the respective gene within a phagemid inside the phage particle. Challenging this phage library with an immobilized antigen allows for in vitro selection of specific binders that can be amplified and identified by reinfection of *Escherichia coli*.

Bacteriophage

The most widely used are the Ff class (f1, fd and M13) which have shown to be 98% homologous. The filamentous M13 phage is most commonly used in phage display technique [94]. An M13 bacteriophage virus that infects only male Gram-negative *E. coli* (bear the F-plasmid) [95, 96], which encodes the F-pilus like (TG1, SS320, ER2738, or XL1-Blue *E. coli*). The infection is mediated by the interaction between F-pilus and g3p of the phage, compared with lytic phage T4 and T7 which lyses and killing the bacteria cell while the M13 bacteriophage infected the host cell without effected on it (continue to growth and divide).

The phage is 6.5 nm in diameter and 930 nm in length with a covalently closed single-stranded genome of 6400 nucleotides coding for 11 different viral proteins (pipit) present within the coat proteins [97]. Five of the 11 proteins (pIII, pVI, pVII, pVIII, and pIX) make up the flexible protein cylinder, 2 (pII and pX) are involved in single-stranded DNA (ssDNA) [98] replication and 3 are required for phage particle assembly. The length of the cylinder is composed of 2700 molecules of the major coat protein (pVIII) while the minor coat proteins (pVII and pIX) are found at one end of the phage particle with 5 molecules of both gene products. There are approximately 5 copies of the other minor coat proteins (pIII and pVI) at the other end of the phage particle. The packaging signal is located at the pVII and pIX end of the phage particle and this is the first region to be assembled. Such libraries are generated by genetic fusion of genes of interest to those of phage coat proteins (pIII or pVIII) [99] using a special phagemid vector which is then transformed in *E. coli*. the gene 3 protein (g3p) is most commonly used for displaytechnology [100,101].

M13K07 Life Cycle

The infection process is a multistep process involving the F pilus on the surface of the cell, and the phage comes in contact with the pilus of *E.coli*, it retracts drawing the phage particle into the cell. Pilus formation is at its most abundance at mid-exponential phase of growth and decreases with increasing growth profile. The outer membrane bacterial proteins (TolQ, R and A) are needed for translocation of the filamentous phage DNA into the cytoplasm and the translocation of the phage coat proteins into the cytoplasmic membrane.

The initiation of infection occurs upon binding of the tip of the F pilus to the pIII phage protein. The pIII phage protein consists of 3 domains (N1, N2 and CT) separated by glycine-rich regions. Each domain is essential for bacterial infection. The N1 and N2 domains are in close proximity and N2 is responsible for binding to the F pilus. The N1 domain interacts with the bacterial membrane protein (TolA-D3) and the phage is retracted towards the bacterium surface where the major and minor phage capsid proteins are disassembled and the phage DNA is translocated into the cytoplasm. The viral (+) phage ssDNA strand enters the cytoplasm and the complementary (-) DNA strand is synthesised by bacterial enzymes. This replicative form (RF) is the template for transcription and phage protein translation [102]. The pII protein cleaves the intergenic region of the positive strand of the RF which acts as a primer for synthesis of a new viral strand by a rolling-circle replication method continuing until 200 copies are within the cell. This continues until pV approaches a crucial level where it binds to newly synthesised viral ssDNA. The newly synthesised ssDNA-pV (800 nm in length and 8 nm in diameter) is assembled in the cytoplasm of the bacterium and the phage particle is subsequently secreted from the cell. This is then cleaved and used as a template for further phage propagation. Approximately 1000 phage per cell are produced in the first hour with 100 – 200 phage particles in subsequent cycles consideration of a vector for the display of proteins or peptides as coat protein fusions to pVIII or pIII is important.

In phage vectors the gene is inserted directly into the genome and expressed with multiple copies of displayed protein leading to polyvalent display. This causes the selection of lower affinity variants during the bio panning process. To avoid an avidity affect a monovalent phage display process was developed using a phage-plasmid vector (phagemid). This is a plasmid with a plasmid origin of replication and a phage-derived origin of replication. The vector is capable of producing large quantities of pIII-fusion proteins but cannot make phage. This is aided by the addition of helper phage (i.e. M13K07 and VCSM13) that supply all the phage enzymes and proteins needed for phage replication [103]. Such libraries are produced by genetic fusion of genes interest to those of phage coat proteins (pIII orpVIII) [104,105] using a special phagemid vector which is then transformed to *E. coli*. Phagemids in both *E. coli* and a phage contain a specific replication origin and a selection marker resistance. However, phagemids lack genes that responsible for replication, packaging, as well as coat proteins, therefore dependent on helper phages which are co-infected with the phagemids into host bacteria enables the phage to encode the required proteins for generating complete phage particles [106], leading to release of phageparticles necessary for encoded protein on their tip (display). The flori allow the synthesis of a single-stranded DNA and the formation of virions. These virions are produced by *E.coli* cells that possess these vectors by infecting the cells with helper phage, and nanobodies are easily selected by phage display [75].The technique used for the selection of suitable antibody by the exposing the phage library to an immobilized antigen, named bio-panning [107,108] or panning for short.

Bio-panning

The bio-panning technique is screened for selection antibody fragments or peptides presented on the phage surface are more efficient for clone screening, since it allows isolating clones with defined specificity and affinity [109]. This technique involves the incubation phage-displayed antibodies with an immobilized target antigen [110,111]. Unbound phages are eliminated by washing, while, phages that specifically bind the target are eluted. Specifically bound phage can be eluted from the immobilized antigen using acidic solutions such as "HCl or glycine buffer" [112],

or basic solutions such as triethylamine [113], or this processes can take place by cleavage the protease site incorporated in the recombinant coat protein [114], or occur through competition with excess antigen [110]. In the next step, the eluted phages are amplified in *E. coli*.

Indeed, only one round of selection is required. To avoid the presence of unspecific background phage, several rounds of selection can be repeated and necessary to getting a clone with high affinity to the target antigen (approximately 2-4 rounds).

Production of Antibodies by Phage Display

The top panel a repertoire of scFv is produced with polymerase chain reaction (PCR). The build of repertoires chain can be occur either from VH and Vk genes in vivo or from V gene segment in vitro. The repertoire of a scFv gene is cloned into phage vector in a way that fuses the scFv gene to a gene III that encodes a protein pIII expressed on the phage surface. In the medial panel, the vector directs *E.coli* to produce phage antibodies, which have a functional scFv fused to pIII on their surface. Inside each phage antibody is the vector DNA containing the gene for the scFv. Phage antibodies binding a specific antigen can be separated from non-binding phage antibodies by affinity on immobilized antigen (bottom panel). A single round of selection increased the number of antigen –binding phage antibodies by a factor ranging from 20 to 1000, depending on antibody affinity. Eluted phage antibodies use infected *E.coli* which then produces more phage antibodies for the next round of selection. Repeated rounds selection is improve to isolate antigen-binding phage antibodies that were originally found at repeats of less than 1 in a billion [113]. One of the hallmark characteristics of phage display technology is the capacity to produce very large libraries of peptides [93] the power of phage display technology results from its ability to establish a physical connection between phenotype (displayed peptide) and genotype (DNA sequence encoding the displayed peptide). This phenotype-genotype link forms the cornerstone of phage display methodology and makes it possible for researchers to isolate target-avid ligands displayed on the phage.

Vector Systems

The vector also named "plasmid" is extra chromosomal, and double-stranded, generally circular DNA sequences that are capable of automatically replicating in a host and that are found in prokaryotes and eukaryotes [115]. Usually, plasmids often have genes that may support the survival of the organism, for example, antibiotic resistance while the artificial plasmids are commonly used as vectors in molecular cloning, leading to driving the replication of recombinant DNA sequences within the host. In vivo, there are many plasmids, and this study used the one of them is pComb3XSS.

The pComb3XSS plasmid

The pComb3x vector was constructed as an origin of pComb3x; it's self-derived from the pBluescript vector by Barbas et al., [116]. The Pcomb3XSS system is used for the expression of the Fab fragment, and cloning in *E. coli*, carried the nanobody gene fragment (obtained from the immunization camel), with phagemid pComb3XSS for a library construction.

The pComb3XSS plasmid has many features are good for cloning:

- The plasmid contains an origin replication that facilitates the semi-independent replication of plasmid within the host .
- The plasmid has genes encoded for antibiotic resistance which helps the host cell to maintenance in an environment.

- Plasmid presents widely in many bacteria, like *Escherichia coli*, and may also be found in some eukaryotes such as yeast, *Saccharomyces cerevisiae* [117].
- The bacteria containing the plasmids can produce millions of copies of the vector within in hours, and the amplified vectors can be then extracted for further manipulation.
- The plasmid has multiple restriction enzyme cleavage sites that allow for the insertion of the desired fragment insert which is benefit used for cloning purposes in the laboratory.

Cancer.

In general, the cells in the body divide grow and die in an orderly manner, but sometimes these cells divide abnormally and uncontrolled [118] which leads to call Cancer. Cancer is the global disease leading cause of death [119], which is caused by genetic mutation or abnormal metabolism observed within cells. The factors causing the cancer are:

- External factors like (tobacco, an infectious organism, chemicals, and radiation) [120-122].
- Internal factors like inherited mutation, hormones, immune condition and mutations that occur from metabolism [120,122,123].

There are different types of receptors on some cells of the body are hormone receptors are proteins found on normal some cells that take up the hormone signals telling the cells to grow like estrogen receptor (ER), progesterone receptor (PR) and protein receptors called human epidermal growth factor receptor (HER2). These receptors play a critical role in the growth of normal cells and developing cancer. In this study will focus on protein receptors human epidermal growth factor 2 (HER2).

Epidermal Growth Factor Receptor Family (EGFR)

The epidermal growth factor receptor (EGFR), also named ErbB protein, belongs to a family tyrosine kinase. This family of receptors is expressed in normal tissues and plays in the control of most fundamental cellular processes like the cell cycle, cell migration, cell metabolism and survival, as well as cell proliferation and differentiation, also plays role in the pathogenesis of several human cancers and another disease:

- Insufficient ErbB signaling is associated with the development of neurodegenerative diseases in humans, such as multiple sclerosis and Alzheimer's disease [124].
- Excessive ErbB signaling is associated with the development of a wide variety of types of solid tumor.

The HER family is made up of four main members [125-129] are including:

- HER-1 (ErbB1).
- HER-2 (ErbB2).
- HER-3 (ErbB3).
- HER-4 (ErbB4).

These proteins are encoded by distinct genes that are expressed on chromosomes 7, 17, 12, and 2, respectively.

Proteins in the EGFR family (HER2, HER2, HER3, and HER4) are all trans-membrane proteins sharing a common basic molecular structure, which are composed of three major distinct regions, they are:

- N – Terminal extracellular domain (ECD).
- Single α - helix trans-membrane domain(TM).
- Intracellular tyrosine kinase domain [130].

Human Epidermal Growth Factor Receptor 2 (HER2)

The human epidermal growth factor receptor 2 (HER2) is a glycoprotein with several alternative names like (ErbB2, CD340, or proto-oncogene neu or p185^{HER2}) [131,132]. The human epidermal growth factor receptor 2 consists of 1255 amino acid, they live on the outside of some cells and receive signals from the body [133]; its encoded by the HER2/neu oncogenic located at the long arm of human chromosome 17 [134].

Correlation between Human Epidermal Growth Factor Receptor 2 and Cancer.

In normal cells, activation of HER2 controls normal cell growth, differentiation, and motility [135], and the number of HER2 receptors per cell is between 20000-50000, while in cancer cells deregulation of these pathways and increased expression of HER-2/neu to 2 million [136] promotes tumor cell growth and migration. Overexpression of HER2 is a correlation with HER2 gene. Amplification of the HER2 gene and over expression of HER2 protein product induces cell transformation and then lead to tumor aggressiveness and an increased probability for recurrent disease.

The human epidermal growth factor receptor 2 (HER2) is expressed in many tissues and its major role in these tissues is to facilitate excessive/uncontrolled cell growth and tumorigenesis [134,137], and becomes more aggressive and more resistant for treatment. For example in the breast cancer, HER2 over-expression about 20% – 30% [27], gastric cancer [138], salivary duct carcinomas [139], esophageal cancer, ovarian cancer, stomach and adenocarcinoma of the lung [140], pancreatic cancer and uterine serous endometrial cancer [141].

Breast cancer is the most common malignancy and the leading cause of cancer-related death among women all around the world [142] and it is after lung cancer [143]. Breast cancer is a complex and heterogeneous disease, molecular profile, and clinical behavior which require different treatment [144]. The gene amplification and/or over expression of HER2 occur in 20 - 30% of breast cancer [145-147], that's lead to increased cell proliferation, tumor invasiveness, accelerated angiogenesis and reduced apoptosis which ultimately translate into aggressive disease, resistance to traditional systemic therapy and decrease survival [148,149].

Mechanism of Human Epidermal Growth Factor Receptor 2 in Breast Cancer and signaling Pathway

The human epidermal growth factor receptor 2 (HER2) different from other EGFR family members, is as an “orphan receptor “due to lacking a known ligand [150]. HER2 signaling is a complex network comprised of membrane receptor and their ligands protein kinase and regulating genes that affect various cellular functions. The formation HER2 is either heterodimers or homodimer, and after activates the intracellular tyrosine kinase, then triggers the autophosphorylation of specific tyrosine residues. The phosphorylation of tyrosine in turn adaptor proteins or enzymes to initiate a succession of signaling cascades to regulate cellular processes [151,152]. The induction of PI3K signal activities is aroused by the heterodimer composed of HER2 and HER3. However, as for as Ras/Raf/MAPK signaling pathway, it can be activated by all of the dimers containing HER2 “HER1/HER2, HER2/HER2, HER2/HER3 and HER2/HER4” [153]. The HER2 pathway has been described in systems biology terms as a complex biological network comprised of three layers, an input layer of membrane receptors and their ligands to trigger the signal coming from outside the cell, a core system processing layer of protein kinases transmitting the signal to the nucleus, and an output layer of transcription factors regulating genes that affect various cellular functions.

Diagnosis of Positive Human Epidermal Growth Factor Receptor 2 in Breast Cancer.

There are various methods for determining HER2 status, like immunohistochemistry (IHC), enzyme-linked immune-sorbent assay (ELISA) analysis and Western blot test for HER2 protein over expression, while fluorescence in situ hybridization (FISH), chromogenic in situ hybridization (CISH), silver in situ hybridization (SISH), Southern blot and polymerase chain reaction (PCR) for HER2/neu gene amplification [154,155]. HER2 positive of breast cancer remains a threatening health problem in both developed and developing countries a critical target for developing therapeutic drugs against HER2 positive of breast cancer, and there are many therapies for treating of the breast cancer depending on the diagnosis.

Types of cancer therapies

There are four types of cancer therapies:

1. Chemotherapy: is a type of cancer treatment, and involves a large group of cytotoxic drugs that interfere with cell division and DNA synthesis, and then kill cancer cells.

2. Hormonal therapy: is a cancer treatment that slows or stops the growth of cancer that uses hormones to grow. Hormone therapy is additionally known as hormonal therapy, hormone treatment, or endocrine therapy.

3. Targeted therapy: It is a type of cancer treatment that targets the changes in cancer cells that help them grow, divide, and spread, and most targeted therapies are either small-molecule drugs that are a small enough to enter cells easily, so they are used for targets that are inside cell or monoclonal antibodies are drugs that are not able to enter cells easily. Instead, they attach to specific targets on the outer surface of cancer cells

4. Immunotherapy: is a type of treatment that helps the immune system fight cancer. There are several types of immunotherapy used to treat cancer. These treatments can either help the immune system attack cancer directly or stimulate the immune system in a more general way.

Many treatments targeted the HER2 by clinically approved drugs. The two keys domains of the HER2: the extracellular domain and the tyrosine kinase domain have been targeted to block the HER2 signaling. There are many antibodies targeting the extracellular domain of HER2 that exists in an open conformation and is a suitable partner for another receptor for dimerization. The dimerization results in the phosphorylation of the intracellular tyrosine kinase domain and activation of downstream signaling pathways. Monoclonal antibodies (MAbs) targeting the extracellular domain of HER2 can be used to suppress its dimerization with other HER family members and therefore block the pathways [153]. Immunoglobulin therapies, also known as a normal human immunoglobulin (NHIG) and used to treat a number of breast cancers, example is: Trastuzumab, Pertuzumab and Lapatinib.

References

1. Kelly BT, Grayson MH. Immunoglobulin E, what is it good for? *Ann Allergy Asthma Immunol* 2016; 116(3):183-187.
2. Abbas AK, Lichtman AH, Pillai S. *Basic Immunology: Functions and Disorders of the Immune System*. Elsevier Health Sciences, 2014.
3. Ueda M, Berger M, Gale RP, Lazarus HM. Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. *Blood Reviews*, 2018;32(2): 106-115.

4. Polo E, Puertas S, Moros M, Batalla, P, Guisán JM, Jesús M, Grazú V. Tips for the functionalization of nanoparticles with antibodies. In *Immobilization of Enzymes and Cells*, 2016, PP:149-163.
5. Padlan EA. Anatomy of the antibody molecule. *Molecular Immunol*, 1994;31(3): 169-217.
6. Liu H, May K. Disulphide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. *MABs* 2012;4(1):17-23.
7. Nelson AL. Antibody fragments: hope and hype. *MABs* 2010;2(1):77-83).
8. Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NBM, Hamid M. scFv antibody: principles and clinical application. *Clin Develop Imm*, 2012. 2012:980250.
9. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. *Nature Reviews Immunol* 2010;10(5):317.
10. Delves PJ, Roitt IM. The immune system. *New Eng J Med* 2000;343(1):37-49.
11. Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. *Frontiers Imm*, 2014;5:520.
12. Forthall DN. Functions of antibodies. *Microbiol Spectr* 2014; 2: 1–17.
13. Geisberger R, Lamers M, Achatz G. The riddle of the dual expression of IgM and IgD. *Immunology*, 2006;118(4):429-437.
14. Underdown BJ, Schiff JM. Immunoglobulin A: strategic defense initiative at the mucosal surface. *Ann Rev Immunol* 1986;4(1):389-417.
15. Pier GB, Lyczak JB, Wetzler LM, Ruebush MJ. eds. *Immunology, Infection, and Immunity*, 2004, PP:196-197.
16. Chen K, Xu W, Wilson M, He B, Miller NW, Bengten E, et al. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell–stimulating programs in basophils. *Nature Immunol* 2009;10(8):889.
17. Conroy PJ, Hearty S, Leonard P, O’Kennedy RJ. Antibody production, design and use for biosensor-based applications. *Seminars Cell Develop Bio* 2009;20(1):10-26.
18. Newcombe C, Newcombe AR. Antibody production: polyclonal-derived biotherapeutics. *J Chromatography B* 2007;848(1):2-7.
19. Pohanka M. Monoclonal and polyclonal antibodies production-preparation of potent biorecognition element. *J Appl Biomed*, 2009;7:115-121.
20. Torrance L, Ziegler A, Pittman H, Paterson M, Toth R, Eggleston I. Oriented immobilisation of engineered single-chain antibodies to develop biosensors for virus detection. *J Virol Meth*, 2006;134(1-2):164-170.
21. Reichert JM. Antibodies to watch in 2016. *MABs* 2016;8(2):197-204.
22. Deb R, Chakraborty S, Veeregowda B, Verma AK, Tiwari R, Dhama, K. Monoclonal antibody and its use in the diagnosis of livestock diseases. *Advan Biosci Biotech* 2013; 4(04):50.
23. Wilson K, Walker J. Principles and techniques of biochemistry and molecular biology. Cambridge University Press, 2010..
24. Gupta SK, Singla LD. Diagnostic trends in parasitic diseases of animals. *Veterinary Diagnostics: Current Trends*. In: Gupta RP, Garg SR, Nehra V and Lather D (Eds), Satish Serial Publishing House, Delhi, 2010, PP:81-112.
25. Lelli D, Moreno A, Brocchi E, Sozzi E, Capucci L, Canelli E, Barbieri I, Zeller H, Cordioli P. West Nile virus: characterization and diagnostic applications of monoclonal antibodies. *Virol J* 2012;9(1):81.
26. Tang P, Liang S, Xu J, Wang S, Wang L. Screening of Monoclonal Antibodies for Cancer Treatment. *J Clin Exp Oncol* 2017;7:4. doi: 10.4172/2324-9110.1000225.

27. Mitri Z, Constantine T, O'Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. *Chemotherapy Research and Practice*, 2012; 2012: 743193.
28. Perrot-Applanat M, Di Benedetto M. Autocrine functions of VEGF in breast tumor cells adhesion, survival, migration and invasion. *Cell Adhesion Migration* 2012;6(6):547–553.
29. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *New Eng J Med* 2012;366(26): 2443-2454.
30. Tillib SV, Vyatchanin AS, Muyldermans S. Molecular analysis of heavy chain-only antibodies of *Camelus bactrianus*. *Biochemistry*, 2014;79(12):1382-1390.
31. ElBakri A, Nelson PN, Odeh ROA. The state of antibody therapy. *Human Imm* 2010;71(12):1243-1250.
32. Hamers-Casterman CTSG, Atarhouch T, Muyldermans S, Robinson G, Hammers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. *Nature*, 1993;363(6428):446.
33. Hassanzadeh-Ghassabeh G, Devoogdt N, De Pauw P, Vincke C, Muyldermans S. Nanobodies and their potential applications. *Nanomedicine*, 2013;8(6):1013-1026.
34. Muyldermans S. Nanobodies: natural single-domain antibodies. *Ann Review Biochem*, 2013;82, 775-797.
35. Nguyen VK, Hamers R, Wyns L, Muyldermans S. Loss of splice consensus signal is responsible for the removal of the entire CH1 domain of the functional camel IGG2A heavy-chain antibodies1. *Molecular immunology*, 1999;36(8):515-524.
36. Woolven BP, Frenken LG, van der Logt P, Nicholls PJ. The structure of the llama heavy chain constant genes reveals a mechanism for heavy-chain antibody formation. *Immunogenetics*, 1999;50(1-2):98-101.
37. Vaneycken I, Devoogdt N, Van Gassen N, Vincke C, Xavier C, Wernery U, et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. *FASEB J* 2011; 25(7):2433-2446.
38. Ablynx. (2012). from <http://www.ablynx.com/en/research-development/pipeline>
39. Bever CS, Dong JX, Vasylieva N, Barnych B, Cui Y, Xu ZL, et al. VHH antibodies: emerging reagents for the analysis of environmental chemicals. *Analytic Bioanalytic Chem*, 2016;408(22):5985-6002.
40. Vu KB, Ghahroudi MA, Wyns L, Muyldermans S. Comparison of llama VH sequences from conventional and heavy chain antibodies. *Molecular immunology*, 1997; 34(16-17):1121-1131.
41. Su C, Nguyen VK, Nei M. Adaptive evolution of variable region genes encoding an unusual type of immunoglobulin in camelids. *Mole Biol Evolution*, 2002;19(3): 205-215.
42. Greenberg AS, Avila D, Hughes M, Hughes A, McKinney EC, Flajnik MF. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. *Nature* 1995;374(6518):168–173.
43. Nuttall SD, Krishnan UV, Hattarki M, De Gori R, Irving RA, Hudson PJ. Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries. *Mol Immunol*.2001;38(4): 313–326.
44. Smolarek D, Bertrand O, Czerwinski M. Variable fragments of heavy chain antibodies (VHHs): a new magic bullet molecule of medicine?. *Adv Hygi Exp Med* 2002;66: 348-358.

45. Oliveira S, Heukers R, Sornkom J, Kok RJ, en Henegouwen PMVB. Targeting tumors with nanobodies for cancer imaging and therapy. *J Cont Release*, 2013;172(3): 607-617.
46. Määttänen P, Gehring K, Bergeron JJ, Thomas DY. Protein quality control in the ER: the recognition of misfolded proteins. In *Seminars in cell & developmental biology* 2010;21(5):500-511.
47. Smith MH, Ploegh HL, Weissman JS. Road to ruin: targeting proteins for degradation in the endoplasmic reticulum. *Science*, 2011;334(6059):1086-1090.
48. Hendershot L, Bole D, Kearney JF. The role of immunoglobulin heavy chain binding protein: in immunoglobulin transport. *Immunology today*, 1987;8(4):111-114.
49. Nguyen VK, Desmyter A, Muyldermans S. Functional heavy-chain antibodies in Camelidae. *Adv Immunol* 2001;79:261-296.
50. Siontorou CG. Nanobodies as novel agents for disease diagnosis and therapy. *Int J Nanomedicine*, 2003;8:4215.
51. Vincke C, Muyldermans S. Introduction to heavy chain antibodies and derived nanobodies. *Meth Mol Biol* 2012; 911:15-26.
52. Eyer L, Hruska K. Single-domain antibody fragments derived from heavy-chain antibodies: a review. *Vet Med*, 2012;57(9):439-513.
53. Baral TN, MacKenzie R, Ghahroudi MA. Single domain antibodies and their utility. *Current Protocols Immunol* 2013;103(1):2-17.
54. Herce HD, Schumacher D, Schneider AF, Ludwig AK, Mann FA, Fillies M, et al. Cell-permeable nanobodies for targeted immunolabelling and antigen manipulation in living cells. *Nature Chem* 2017;9(8):762.
55. Helma J, Cardoso MC, Muyldermans S, Leonhardt H. Nanobodies and recombinant binders in cell biology. *J Cell Biol*, 2015;209(5):633-644.
56. Akazawa-Ogawa Y, Takashima M, Lee YH, Ikegami T, Goto Y, Uegaki K, Hagihara Y. Heat-induced irreversible denaturation of the camelid single domain VHH antibody is governed by chemical modifications. *J Biol Chem*, 2014; 289(22):15666-79.
57. Walper SA, Battle SR, Lee PAB, Zabetakis D, Turner KB, Buckley PE, et al. Thermostable single domain antibody–maltose binding protein fusion for *Bacillus anthracis* spore protein BclA detection. *Analytic Biochem*, 2014;447:64-73.
58. Goldman ER, Brozozog-Lee PA, Zabetakis D, Turner KB, Walper SA, Liu JL, et al. Negative tail fusions can improve ruggedness of single domain antibodies. *Protein Expression Purification*, 2014;95:226-232.
59. Roovers RC, Vosjan MJ, Laeremans T, el Khoulati R, de Bruin RC, Ferguson KM, et al. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. *Int J Cancer*, 2011;129(8):2013-2024.
60. Richard G, Meyers AJ, McLean MD., Arbabi-Ghahroudi M, MacKenzie R, Hall JC. In vivo neutralization of α -cobratoxin with high-affinity llama single-domain antibodies (VHHs) and a VHH-Fc antibody. *PLoS One*, 2013;8(7): 469-495.
61. Klein Á, Kovács M, Muskotál A, Jankovics H, Tóth B, Pósfai M, Vonderviszt F. Nanobody-Displaying Flagellar Nanotubes. *Scientific Reports*, 2018;8(1):3584.
62. Rahbarizadeh F, Rasae M, Moghadam M, Allameh A, Sadeghizadeh M. Induction of immune response in *Camelus bacterianus* and *Camelus dromedaries* against MUC1-peptide with efficient combining properties. *J Camel Pract Res*, 2004;11:1-9.

63. Salema V, Fernández LÁ. High yield purification of nanobodies from the periplasm of *E. coli* as fusions with the maltose binding protein. *Protein Experiment Purification* 2018;91: 42–48.
64. Holliger P. Expression of antibody fragments in *Pichia pastoris*. *Methods Mol Biol* 2002;178: 349–357.
65. De Meyer T, Laukens B, Nolf J, Van Lerberge E, De Rycke R, De Beuckelaer A, et al. Comparison of VHH-Fc antibody production in *Aspergillus nidulans*, *Nicotiana benthamiana* and *Pichia pastoris*. *Plant Biotechnol J*, 2015;13(7):938-947.
66. Kijanka M, Dorresteyn B, Oliveira S, van Bergen en Henegouwen PM. Nanobody-based cancer therapy of solid tumors. *Nanomedicine*, 2015;10(1):161-174.
67. Chakravarty R, Goel S, Cai W. Nanobody: the “magic bullet” for molecular imaging?. *Theranostics*, 2014;4(4):386.
68. Ebrahimzadeh W, Gargari SM, Rajabibazl M, Ardekani LS, Zare H, Bakherad H. Isolation and characterization of protective anti-LPS nanobody against *V. cholerae* O1 recognizing Inaba and Ogawa serotypes. *Appl Microb Biotechnol*, 2013;97(10):4457-4466.
69. Rahbarizadeh F, Rasaei MJ, Forouzandeh M, Allameh AA. Over expression of anti-MUC1 single-domain antibody fragments in the yeast *Pichia pastoris*. *Molecular Imm*, 2006;43(5):426-435.
70. Ladenson RC, Crimmins DL, Landt Y, Ladenson JH. Isolation and characterization of a thermally stable recombinant anti-caffeine heavy-chain antibody fragment. *Analytic Chem*, 2006;78(13):4501-4508.
71. Abbady AQ, Al-Shemali R, Assaad JM, Murad H. Generation and characterization of nanobodies against rhGH expressed as sfGFP fusion protein. *General Comp Endocrinol*, 2014;204:33-42.
72. Yan J, Li G, Hu Y, Ou W, Wan Y. Construction of a synthetic phage-displayed Nanobody library with CDR3 regions randomized by trinucleotide cassettes for diagnostic applications. *J Translational Med*, 2014;12(1):343.
73. Zabetakis D, Anderson GP, Bayya N, Goldman ER. Contributions of the complementarity determining regions to the thermal stability of a single-domain antibody. *PloS one*, 2013;8(10):77678.
74. Turner KB, Liu JL, Zabetakis D, Lee AB, Anderson GP, Goldman ER. Improving the biophysical properties of anti-ricin single-domain antibodies. *Biotechnol Reports*, 2015;6:27-35.
75. Hu Y, Liu C, Muyldermans S. Nanobody-based delivery systems for diagnosis and targeted tumor therapy. *Frontiers Immunol*, 2017;8:1442.
76. Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, Muyldermans S, Revets H. Efficient cancer therapy with a nanobody-based conjugate. *Cancer research*, 2004;64(8):2853-2857.
77. Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. *Expert Opinion Biological Ther*, 2005;5(1):111-124.
78. Schilling J, Clevinger B, Davie JM, Hood L. Amino acid sequence of homogeneous antibodies to dextran and DNA rearrangements in heavy chain V-region gene segments. *Nature*, 1980;283(5742):35.
79. Tonegawa S. Somatic generation of antibody diversity. *Nature*, 1983;302 (5909): 575-581.
80. Tsuruta LR, Moro AM. Display Technologies for the Selection of Monoclonal Antibodies for Clinical Use. In: *Antibody Engineering*, Thomas Böldicke, 2017, Intech Open, DOI: 10.5772/intechopen.70930.

81. Yonezawa M, Doi N, Higashinakagawa T, Yanagawa H. DNA display of biologically active proteins for in vitro protein selection. *J Biochem*, 2004;135(3): 285-288.
82. Doi N, Yanagawa H. STABLE: protein-DNA fusion system for screening of combinatorial protein libraries in vitro. *FEBS Letters*, 1999;457(2):227-230.
83. Pardon E, Laeremans T, Triest S, Rasmussen SG, Wohlkönig A, Ruf A, et al. A general protocol for the generation of Nanobodies for structural biology. *Nature Protocols*, 2014;9(3):674.
84. Galan A, Comor L, Horvatic A, Kules J, Guillemin N, Mrljak V, Bhide M. Library-based display technologies: where do we stand? *Mol BioSyst* 2016;12: 2342–2358.
85. Leow C, Fischer K, Cheng Q, Chuah C, McCarthy J. Single domain antibodies as new biomarker detectors. *Diagnostics*, 2017;7(4):52.
86. Kronqvist N, Löfblom J, Jonsson A, Wernérus H, Ståhl S. A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry. *Protein Eng Design Select*, 2008;21(4):247-255.
87. Fleetwood F, Devoogdt N, Pellis M, Wernery U, Muyldermans S, Ståhl S, Löfblom J. Surface display of a single-domain antibody library on Gram-positive bacteria. *Cell Mol Life Sci* 2013;70: 1081–1093.
88. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. *Nature Biotechnol*, 1997;15(6):553.
89. Plückthun A. Ribosome display: a perspective. *Methods Mol Biol* 2012;805:3-28.
90. Lipovsek D, Plückthun A. In-vitro protein evolution by ribosome display and mRNA display. *J Immunol Methods*, 2004;290(1-2):51-67.
91. Verheesen P, Laeremans T. Selection by phage display of single domain antibodies specific to antigens in their native conformation. *Methods Mol Biol* 2012; 911:81-104.
92. Frenzel A, Schirrmann T, Hust M. Phage display-derived human antibodies in clinical development and therapy. *MAbs* 2016;8(7):1177-1194.
93. Aghebati-Maleki L, Bakhshinejad B, Baradaran B, Motallebnezhad M, Aghebati-Maleki A, Nickho H, et al. Phage display as a promising approach for vaccine development. *J Biomed Sci* 2016;23(1):66.
94. Rakonjac j. Filamentous bacteriophages: biology and applications. Chichester, 2012..
95. Marvin DA, Hoffmann-Berling H. A fibrous DNA phage (fd) and a spherical RNA phage (fr) specific for male strains of E coli. *Zeitschrift für Naturforschung B*, 1963;18(11):884-893.
96. Criscuolo E, Spadini S, Lamanna J, Ferro M, Burioni R. Bacteriophages and their immunological applications against infectious threats. *J Immunol Research*, 2017; 2017:3780697. doi: 10.1155/2017/3780697.
97. Goodrich AF, Steege DA. Roles of polyadenylation and nucleolytic cleavage in the filamentous phage mRNA processing and decay pathways in *Escherichia coli*. *RNA* 1999;5(7):972-985.
98. Mai-Prochnow A, Hui JG, Kjelleberg S, Rakonjac J, McDougald D, Rice SA. Big things in small packages: the genetics of filamentous phage and effects on fitness of their host. *FEMS Microbial Review* 2015; 39(4):465-87.
99. Menéndez T, Santiago-Vispo NF, Cruz-Leal Y, Coizeau E, Garay H, Reyes O, et al. Identification and characterization of phage-displayed peptide mimetics of *Neisseria meningitidis* serogroup B capsular polysaccharide. *Int J Medical Microb*, 2011;301(1):16-25.

100. Kügler J, Nieswandt S, Gerlach GF, Meens J, Schirrmann T, Hust M. Identification of immunogenic polypeptides from a *Mycoplasma hyopneumoniae* genome library by phage display. *Appl. Microbiol. Biotechnol*, 2008;80(3):447.
101. Meyer T, Schirrmann T, Frenzel A, Mieth S, Stratmann-Selke J, Gerlach GF, et al. Identification of immunogenic proteins and generation of antibodies against *Salmonella Typhimurium* using phage display. *BMC Biotechnol*, 2012; 12(1):29.
102. Marlovits TC, Kubori T, Sukhan A, Thomas DR, Galan JE, Unger VM. Structural insights into the assembly of the type III secretion needle complex. *Science* 2004;306:1040-1042.
103. Barbas CF, Burton DR, Scott JK, Silverman GJ. *Phage Display: A Laboratory Manual*, 2001, Cold Spring Harbor Laboratory Press.
104. Hoogenboom HR. Selecting and screening recombinant antibody libraries. *Nat. Biotechnol.* 2005;23:1105.
105. Arbabi-Ghahroudi M, MacKenzie R, Tanha J. Selection of non-aggregating VH binders from synthetic VH phage-display libraries. *Methods Mol. Biol* 2009; 525:187.
106. Sidhu SS. Engineering M13 for phage display. *Biomolecular Engineering*, 2001;18(2):57-63.
107. Pande J, Szewczyk MM, Grover AK. Phage display: concept, innovations, applications and future. *Biotechnol Advan* 2007; 28(6):849-858.
108. He B, Chai G, Duan Y, Yan Z, Qiu L, Zhang H, et al. BDB: biopanning data bank. *Nucleic Acids Research*, 2015;44(D1):1127-1132.
109. Parmley SF, Smith GP. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. *Gene*, 1988;73(2):305-318.
110. Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries. *Nature*, 1991;352(6336):624.
111. Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, et al. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. *EMBO J* 1994;13(3):692-698.
112. Kang AS, Barbas CF, Janda KD, Benkovic SJ, Lerner RA. Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. *Proceed Nation Acad Sci*, 1991;88(10):4363-4366.
113. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter, G. By-passing immunization: human antibodies from V-gene libraries displayed on phage. *J Mole Bio* 1991;222(3):581-597.
114. Kristensen P, Winter G. Proteolytic selection for protein folding using filamentous bacteriophages. *Folding Design*, 1998;3(5):321-328.
115. Palomares LA, Estrada-Moncada S, Ramírez OT. Production of recombinant proteins. In *Recombinant gene expression 2004*;PP:15-51.
116. Barbas CF, Kang AS, Lerner RA, Benkovic SJ. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. *Proceed Nation Acad Sci*, 1991;88(18):7978-7982.
117. Brown TA. *Vectors for Gene Cloning: Plasmids and Bacteriophages*. In: *Gene Cloning and DNA Analysis: An Introduction*, 6th Ed. John Wiley and Sons, UK, 2010.
118. Kopeina GS, Senichkin VV, Zhivotovsky B. Caloric restriction-A promising anti-cancer approach: From molecular mechanisms to clinical trials. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, 2017;1867(1):29-41.
119. Forouzanfar MH, Afshin A, Alexander LT, Anderson HR, Bhutta, ZA, Biryukov S, et al. Global, regional, and national comparative risk assessment of 79

- behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet*, 2016;388(10053):1659-1724.
120. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. *Nature*, 2009;458(7239):719.
 121. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *Cancer J Clinicians*, 2011;61(2):69-90.
 122. Garraway LA, Lander ES. Lessons from the cancer genome. *Cell*, 2013;153(1):17-37.
 123. Zhang X, Sun Y, Wang P, Yang C, Li S. Exploration of the molecular mechanism of prostate cancer based on mrna and miRNA expression profiles. *Onco Targets Ther*, 2017;10:3225.
 124. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. *Current Opinion Cell Bio*, 2007;19(2):124-134.
 125. Kanthala S, Gauthier T, Satyanarayanajois S. Structure–activity relationships of peptidomimetics that inhibit PPI of HER2-HER3. *Biopolymers*, 2014;101(6):693-702.
 126. Kurata T, Tsurutani J, Fujisaka Y, Okamoto W, Hayashi H, Kawakami H, et al. Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer. *Investig New Drugs*, 2014;32(5): 946-954.
 127. Schroeder R, Stevens C, Sridhar J. Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer. *Molecules*, 2014; 19(9):15196-15212.
 128. Xu C, Chen H, Wang X, Gao J, Che Y, Li Y, et al. S100A14, a member of the EF-hand calcium-binding proteins, is over expressed in breast cancer and acts as a modulator of HER2 signalling. *J Biol Chem*, 2014;289(2):827-837.
 129. Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. *Cancer Metastasis Reviews*, 2015;34(1):157-164.
 130. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *Arch Path Lab Med*, 2013;138(2):241-256.
 131. Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. *Arch Path Lab Medicine* 2011;135:55-62.
 132. Sasso M, Bianchi F, Ciravolo V, Tagliabue E, Campiglio M. HER2 splice variants and their relevance in breast cancer. *J Nucleic Acids Invest* 2011; 2(1), e9. <https://doi.org/10.4081/jnai.2011.2454>.
 133. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *The Lancet*, 2010;376(9742):687-697.
 134. Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: over expression and therapeutic implications. *Molecular Bio Int*, 2014;2014:852748. doi: 10.1155/2014/852748.

135. Pappas A, Lagoudianakis E, Seretis C, Tsiambas E, Koronakis N, Toutouzas K, et al. Clinical role of HER-2/neu expression in colorectal cancer. *J BUON*, 2013;18(1):98-104.
136. Duffy MJ. Predictive markers in breast and other cancers: a review. *Clin Chem*, 2005;51(3):494-503.
137. Baum RP, Prasad V, Müller D, Schuchardt C, Orlova A, Wennborg A, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic ¹¹¹In-or ⁶⁸Ga-labeled affibody molecules. *J Nuclear Med*, 2010;51(6):892.
138. Rüschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, et al. HER2 testing in gastric cancer: a practical approach. *Modern Pathol*, 2012;25(5):637.
139. Chiosea SI, Williams L, Griffith CC, Thompson LD, Weinreb I, Bauman JE, et al. Molecular characterization of apocrine salivary duct carcinoma. *Am J Surgical Pathol*, 2015;39(6):744-752.
140. Kumar V, Abbas A, Aster J. *Robbins Basic Pathology*, 9th Edition, 2012.
141. Buza N, Roque DM, Santin AD. HER2/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges. *Arch Pathol Lab Med* 2014;138(3):343-350.
142. Ghaemian N, Siadati S, Nikbakhsh N, Mirzapour M, Askari H, Asgari S. Concordance rate between fine needle aspiration biopsy and core needle biopsy in breast lesions. *Iran J Pathol*, 2013;8(4):241-246.
143. Landi L, Cappuzzo F. HER2 and lung cancer. *Expert Rev Anticancer Ther* 2013;13(10):1219-1228.
144. Bosch A, Eroles P, Zaragoza R, Viña JR, Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. *Cancer Treat Rev*, 2010;36(3):206-215.
145. Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. *Biochem Soc T*, 2012;40: 139-146.
146. Sclafani F, Roy A, Cunningham D, Wotherspoon A, Peckitt C, Gonzalez de Castro D, et al. HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemo radiotherapy (CRT) with or without cetuximab. *Ann Oncology*, 2013;24(12), 3123-3128.
147. Ballinger TJ, Sanders ME, Abramson VG. Current HER2 testing recommendations and clinical relevance as a predictor of response to targeted therapy. *Clin Breast Cancer*, 2013;15(3):171-180.
148. Banerjee S, Smith IE. Management of small HER2-positive breast cancers. *Lancet Oncology*, 2010;11(12):1193-1199.
149. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. *Cancer Cell*, 2010;18(2):160-170.
150. Cappuzzo F. The human epidermal growth factor receptor (HER) family: structure and function. In *Guide to Targeted Therapies: EGFR Mutations in NSCLC*, 2014, pp: 7-17.
151. Esteva FJ, Pustztai L. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale. *Oncology*, 2005;19:5-16.
152. Schlessinger J. Receptor tyrosine kinases: legacy of the first two decades. *Cold Spring Harbor Perspectives Bio*, 2014;6(3).

153. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. *J Controlled Release*, 2010;146(3):264-275.
154. Moelans CB, De Weger RA, Van der Wall E, Van Diest PJ. Current technologies for HER2 testing in breast cancer. *Critical Rev Oncology/ Hematology*, 2011;80(3):380-392.
155. Endo Y, Dong Y, Yoshimoto N, Asano T, Hato Y, Yamashita H, et al. HER2 mutation status in Japanese HER2-negative breast cancer patients. *Japanese journal of clinical oncology*, 2014;44(7):619-623.